10-Q: Pluri Faces Going Concern Doubt Amid Rising Losses

Pluri Inc. reported increased net losses and a significant working capital deficit, raising substantial doubt about its ability to continue as a going concern, while pursuing diverse biotech ventures.

Summary

• Pluri Inc. reported a net loss of $6.132 million for the three months ended September 30, 2025, an increase from $6.036 million in the same period last year.
• The company's accumulated deficit reached $448.905 million as of September 30, 2025.
• A working capital deficit of $15.239 million was reported as of September 30, 2025, worsening from $10.233 million on June 30, 2025.
• Cash and cash equivalents, short-term bank deposits, restricted cash, and restricted bank deposits totaled $16.393 million as of September 30, 2025.
• Management explicitly stated substantial doubt about the company's ability to continue as a going concern for at least the next twelve months.
• The company's $27.541 million loan from the European Investment Bank (EIB) is due on June 1, 2026, with restructuring discussions ongoing but uncertain.
• The National Institute of Allergy and Infectious Diseases (NIAID) terminated its $4.2 million contract for PLX-R18 cell therapy development, effective April 15, 2025, after $2.3 million in funding was received.
• Research and development expenses, net, increased by 36% to $3.931 million, primarily due to higher salaries, exchange rate differences, and the acquisition of Kokomodo.
• Revenues slightly decreased to $316,000 from $326,000 in the prior year, primarily from CDMO services and AgTech fees.
• Loss per share improved to $(0.65) from $(1.08) due to a significant increase in weighted average shares outstanding (8,995,635 vs. 5,459,236).
• The company continues to advance its diverse pipeline in regenerative medicine, aesthetics and wellness, food technology (Ever After Foods, Kokomodo), agricultural technology (Coffeesai), and CDMO services.

Sentiment

Score: 2

Explanation: The company faces severe liquidity challenges, evidenced by a significant working capital deficit, recurring losses, increased cash burn, and an explicit 'going concern' warning. While there are positive developments in its diverse pipeline and some non-dilutive funding, these are overshadowed by the immediate financial distress and uncertainty surrounding key debt repayment and future capital. The termination of the NIAID contract further compounds funding issues.

Positives

• Net loss attributed to shareholders slightly decreased to $5.850 million from $5.882 million year-over-year.
• Loss per share improved to $(0.65) from $(1.08) due to an increased number of outstanding shares.
• Other financial income (expenses), net, significantly improved from a $621,000 expense to a $439,000 income, driven by exchange rate differences and hedging gains.
• Net cash provided by investing activities increased to $3.850 million from $585,000, primarily from proceeds from short-term deposits.
• The company's Ever After Foods subsidiary successfully raised $10 million in a private placement offering, with Pluri investing $1.25 million.
• The clinical study for the PROTO project (knee osteoarthritis) using PLX-PAD cells was approved by the Paul-Ehrlich-Institut in June 2025.
• New collaborations were established with leading counterparties in Asia, Europe, and the United States for POC or pilot programs across foodtech, AgTech, and cell-based aesthetics and wellness subsidiaries.
• The company launched a novel allogeneic immunotherapy platform utilizing MAIT cells in May 2024, targeting solid tumors.
• PluriCDMO, launched in January 2024, is generating revenues from cell therapy manufacturing services.
• The IIA committed to fund a collaboration with Bar-Ilan University for MAIT cells development for solid tumors, with an initial budget of approximately $166,000.

Negatives

• The company reported an increased net loss of $6.132 million for the quarter, up from $6.036 million in the prior year.
• Accumulated deficit grew to $448.905 million, and total shareholders deficit worsened to $11.360 million.
• The working capital deficit significantly increased to $15.239 million from $10.233 million in the previous quarter.
• Cash used in operating activities increased to $5.428 million, indicating a higher cash burn rate.
• Revenues slightly decreased to $316,000 from $326,000 year-over-year.
• Cost of revenues increased by 59.5% to $201,000, attributed to higher personnel costs for a specific project.
• Research and development expenses, net, increased by 36% to $3.931 million, contributing to higher operating losses.
• The National Institute of Allergy and Infectious Diseases (NIAID) terminated its $4.2 million contract for PLX-R18 cell therapy development, reducing non-dilutive funding.
• The $27.541 million EIB loan is due on June 1, 2026, and discussions for restructuring are ongoing with no certainty of a positive outcome.
• The company explicitly stated it does not have sufficient resources to meet operating obligations for at least twelve months, raising substantial doubt about its ability to continue as a going concern.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring operating losses, negative cash flows, and an accumulated deficit of $448.905 million.
• The company requires additional liquidity resources in the near term to support product commercialization and R&D activities.
• There is no assurance that the company will successfully obtain adequate long-term financing, which could lead to scaling down or discontinuing operations.
• Uncertainty surrounds the outcome of discussions with the European Investment Bank (EIB) regarding the restructuring and potential extension of the $27.541 million loan due June 1, 2026.
• The termination of the $4.2 million NIAID contract for PLX-R18 cell therapy reduces a significant source of non-dilutive funding.
• The company's ability to execute its business plan is dependent on obtaining additional capital, entering licensing/collaboration agreements, providing CDMO services, and securing other funding sources like grants.
• The company is subject to market, political, and economic conditions, including instability in the Middle East and armed conflict involving Israel, which may directly affect its business.
• Developments in international trade policy (tariffs, sanctions) could affect sourcing, distribution, costs, and financial results.
• The company's ability to comply with Nasdaq Capital Market listing rules is a concern given its financial condition.

Future Outlook

The company does not anticipate generating significant revenues from product sales in the next twelve months and expects operating costs to exceed near-term revenues. It will require additional liquidity to support commercialization and R&D. The ability to execute its business plan is dependent on securing additional capital, entering partnerships, providing CDMO services, restructuring the EIB loan, and obtaining non-dilutive funding. Management estimates insufficient resources to meet operating obligations for at least twelve months, raising substantial doubt about the company's ability to continue as a going concern. Operations may need to be scaled down or discontinued if financing is not secured.

Management Comments

• Management estimates that the company does not have sufficient resources to meet its operating obligations for at least twelve months from the issuance date of these interim unaudited condensed consolidated financial statements.
• The company is addressing its liquidity issues by implementing initiatives to allow the continuation of its activities, including a cost-reduction plan.
• There is no assurance that the company will be successful in obtaining an adequate level of financing needed for the long-term development and commercialization of its products, or any financing at all.

Industry Context

Pluri operates in the highly competitive and capital-intensive biotechnology sector, specifically leveraging a 3D cell expansion platform across diverse applications including regenerative medicine, food technology, agricultural technology, and CDMO services. The company's ventures into cultivated meat (Ever After Foods), coffee (Coffeesai), and cacao (Kokomodo) align with growing global trends in sustainable food production and alternative proteins. Its focus on cell therapy, including novel MAIT cells for oncology, positions it within cutting-edge medical research. The termination of the NIAID contract highlights the inherent risks and funding uncertainties in government-backed R&D, while new collaborations in AgTech and foodtech demonstrate efforts to diversify revenue streams and validate its platform across multiple high-growth industries.

Comparison to Industry Standards

• The company's accumulated deficit of $448.905 million and recurring operating losses are common for early-stage biotechnology companies focused on R&D, but the explicit 'going concern' warning indicates a more severe liquidity challenge compared to peers with stronger cash reserves or clearer paths to profitability.
• The increase in R&D expenses by 36% reflects continued investment in its diverse pipeline, which is typical for biotech firms, but without corresponding revenue growth, it exacerbates the cash burn.
• The successful $10 million funding round for Ever After Foods, with Pluri's $1.25 million investment, is a positive sign for its cultivated meat subsidiary, indicating external investor confidence in that specific venture, potentially comparable to funding rounds seen by other cultivated meat startups like Upside Foods or Mosa Meat.
• The termination of the NIAID contract is a setback, contrasting with other biotech companies that often rely on consistent government grants for long-term R&D projects, such as those funded by NIH or BARDA for biodefense applications.

Management Changes

Corporate Governance

Related Party Transactions

• Investment of $1.25 million in Ever After Foods, a majority-owned subsidiary, as part of its $10 million private placement offering.
• Amended and Restated Employment Agreement with Liat Zalts (CFO and Treasurer) detailing compensation and benefits.
• Equity awards granted to Yaky Yanay (CEO) for fiscal year 2025 performance, and potential future grants contingent on performance.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from potential future capital raises (ATM, shelf registration) and existing equity awards. The 'going concern' warning indicates a high risk of substantial or total loss of investment if additional funding is not secured. Increased weighted average shares outstanding already diluted per-share loss.
• **Employees**: The CEO's salary reduction and the CFO's new employment agreement with performance-based bonuses and change-of-control provisions reflect efforts to manage costs and retain key talent amidst financial challenges. The acquisition of Kokomodo adds new employees.
• **Creditors (EIB)**: The $27.541 million loan is due in June 2026, and the uncertainty of restructuring discussions poses a repayment risk. The EIB is also entitled to royalties on future revenues.
• **Customers/Partners**: The termination of the NIAID contract impacts a key partner and a specific product development. However, new collaborations in CDMO, AgTech, and foodtech indicate ongoing engagement and potential for future business development.
• **Suppliers**: Increased cost of revenues, particularly due to higher personnel costs for a specific project, could impact supplier relationships or future project profitability.

Next Steps

• Identify additional liquidity resources in the near term to support product commercialization and R&D activities.
• Continue discussions with the EIB regarding a potential restructuring of the EIB Loan, including a possible extension of its maturity date.
• Obtain sufficient additional capital through various means, including equity offerings (ATM, shelf registration) and non-dilutive sources.
• Enter into licensing or other commercial, partnerships, and collaboration agreements.
• Provide CDMO services to clients to generate revenue.
• Advance activities across foodtech, AgTech, and cell-based aesthetics and wellness subsidiaries, including ongoing POC and pilot programs.
• Continue efforts to enhance flavor and aroma profiles for cultivated coffee through bioprocess optimization and downstream refinement at Coffeesai.
• Achieve certain objectives and accomplishments by December 31, 2025, for the CEO to receive future equity award grants.

Key Dates

Recommendation

The filing presents a dire financial situation, explicitly stating 'substantial doubt about the Company's ability to continue as a going concern' for at least the next twelve months. This is compounded by recurring operating losses, a worsening working capital deficit, and increased cash burn. The $27.541 million EIB loan is due in less than a year with uncertain restructuring outcomes, and a significant non-dilutive funding source (NIAID contract) has been terminated. While the company has a diverse pipeline and some positive developments in subsidiaries, these are far from offsetting the immediate and severe liquidity crisis. The need for significant additional capital, coupled with the high risk of scaling down or discontinuing operations, makes the stock a 'strong sell' for any seasoned investor or institution, as the risk of capital loss is exceptionally high.

Keywords

Biotechnology, Cell Therapy, Regenerative Medicine, Food Technology, Agricultural Technology, CDMO, SEC Filing, 10-Q, Going Concern, PLX Cells, MAIT Cells, Cultivated Meat, Cultivated Coffee, Cultivated Cacao, EIB Loan, NIAID Contract, Nasdaq, Financial Results, Liquidity, R&D